Werewolf Therapeutics/ US95075A1079 /
| 14/11/2024 18:25:55 | Var. -0.08 | Volume | Denaro- | Lettera18:26:03 | Max | Min |
|---|---|---|---|---|---|---|
| 1.98USD | -3.88% | 4,355 Fatturato: 8,677.22 |
-Quantità in denaro: - | 1.97Quantità in lettera: 200 | 2.03 | 1.93 |
GlobeNewswire
08/08
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
25/06
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical ...
GlobeNewswire
01/06
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
30/05
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire
23/05
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
03/05
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
24/04
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 Amer...
GlobeNewswire
23/04
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Pot...
GlobeNewswire
05/04
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammat...
GlobeNewswire
04/04
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform...
GlobeNewswire
07/03
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busin...
GlobeNewswire
06/03
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
GlobeNewswire
05/03
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
GlobeNewswire
08/01
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
GlobeNewswire
14/11/2023
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
03/11/2023
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establish...
GlobeNewswire
31/10/2023
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of C...
GlobeNewswire
27/09/2023
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s ...
GlobeNewswire
11/09/2023
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
GlobeNewswire
24/03/2022
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides ...
GlobeNewswire
16/03/2022
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-12...
GlobeNewswire
15/03/2022
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
